Robert Gellibolian, Ph.D

Founder & Ceo of Cellectgen

Robert has a broad background in business as well as product development and commercialization. He has held senior level management and technical positions at House Ear Institute, Agilent Technologies, and DiscoveRx where he fostered cross-collaborative research focused on the role of inflammation in hearing loss, discovering and commercialization of genetically-engineered cell lines based on novel high-value inflammatory targets, and development and commercialization of a high-density in-situ DNA microarray platform for gene expression profiling and DNA Bioanalyzer platform (co-developed with Caliper, acquired by Perkin Elmer). Robert also acts as an EIR advisor for Children’s Hospital of Los Angeles’ flagship CTIP (Consortium for Technology and Innovation in Pediatrics) program. He has authored multiple peer-reviewed publications and is co-inventor on multiple issued and pending patents. Robert holds a Bachelor of Science degree from UCLA and a Ph.D from Texas A&M University, both in biochemistry. He did his post-doctoral research work at the Salk Institute’s Gene Expression Laboratory in San Diego.